Haseeb Ahmad – Country President, Novartis UK
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Address: Novartis Pharmaceuticals UK Limited, Frimley Business Park, Camberley, Surrey, GU16 7SR, United Kingdom
Tel: +44 (0)1276 692255
Web: http://www.novartis.co.uk/index.shtml
Novartis UK is the UK affiliate of Swiss based Novartis AG – one of the largest and most widely respected pharmaceutical companies in the world. This pioneering and innovative company came about through the merger, in 1996, of two key Swiss pharmaceutical organisations, Ciba Geigy and Sandoz.
Headquartered in Basel, Novartis employs nearly 100,000 people worldwide and has a presence in over 140 countries. Novartis has a well-earned reputation for introducing innovative and effective medicines for disease areas in need of new therapies – particularly in oncology, transplantation and ophthalmology. The company is also known for producing new and ever-more efficient medicines for the more common cardiovascular and respiratory diseases, as well as for diseases affecting the brain.
Novartis currently has a total of 145 development projects in various stages of clinical development, including potential new products and potential new indications or formulations for existing products.
x Cardiovascular and Metabolism
x Hypertension, Diabetes, Atherosclerosis
x Integrated Speciality Medicines
x Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergies
x Infectious diseases, Transplantation and Immunology
x Organ transplants
x Neuroscience
x Alzheimer’s, Parkinson’s, Epilepsy, Multiple sclerosis
x Ophthalmics
x Age-related macular degeneration, Dry eye Haematologic and solid tumour diseases
Novartis Oncology aims to improve and extend the lives of patients with cancer. It has a wide range of therapy areas, and a broad pipeline of new products and new indications.
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
A roundup of the biggest UK pharma news, including the industry’s uncertain position after the UK-US trade accord; Haleon’s full takeover of its Chinese joint venture; AstraZeneca’s acquisition of Belgian…
UK Prime Minister Keir Starmer’s government continues its push to overhaul the country’s iconic National Health Service (NHS). After originally announcing plans to restructure NHS England, the body that manages…
Dr Carolyn H. Rogers, Rushikesh S. Dasoondi and Dr Michael A. Roberts from UK and European intellectual property law firm Reddie & Grose LLP examine the intersection of personalised medicine…
Fiona Carragher, Chief Policy and Research Officer at Alzheimer’s Society, delves into the organization’s mission to transform dementia care through innovation, advocacy, and global collaboration. Carragher addresses critical challenges, including…
Seen by most as life-sciences friendly, the UK Government’s 2024 Autumn Budget not only pledges to increase funding for the country’s ailing National Health Service (NHS), but to dedicate additional…
The participation of Emma Walmsley, CEO of GlaxoSmithKline (GSK), in the FT Live Global Pharma and Biotech Summit coincided with the outcome of the American elections and the historic win…
A roundup of top stories from UK pharma and healthcare, including the innovative manufacturing fund comprised in the government’s new life-sciences-focused budget; GSK’s autoimmune therapy deal with Chimagen Biosciences; Northern…
Medtech-focused recruitment consultant Ivor Campbell casts his eye over the profiles the global medtech industry needs most today. Campbell argues that while specialist scientists and engineers remain as important as…
The newly elected UK government’s Secretary of State for Health and Social Care Wes Streeting has a full plate of challenges ahead. Britain’s National Health Service (NHS) is plagued with…
Throughout his long career, John-Arne Rottingen has gathered experience across multiple domains from discovery research to public health and diplomacy that led him to become the founding CEO of the…
A roundup of some of the biggest stories coming out of the UK pharma industry, including AstraZeneca’s bid for cancer specialist Fusion Pharmaceuticals; the shutdown of Sanofi’s R&D site in…
Last year the UK-based pharma industry warned against the country’s waning competitiveness, condemning the government’s statutory scheme designed to control drug prices. UK-headquartered AstraZeneca joined the battle cry, claiming it…
See our Cookie Privacy Policy Here
